All information on this website is intended strictly for educational and research purposes only.
The content on OpenPep — including peptide profiles, clinical trial summaries, dosing information, and reconstitution calculators — must not be used for:
OpenPep aggregates publicly available clinical trial data and research. We do not sell, distribute, or recommend any substances. All AI-generated summaries are interpretations of published research and may contain errors.
ACE-031 (Activin Receptor Type IIB Decoy)
For educational and research purposes only. Not medical advice.
ACE-031 showed impressive muscle increases in Duchenne muscular dystrophy trials but was discontinued due to unexpected vascular side effects (nosebleeds, telangiectasia). Demonstrates the potency and risk of broad myostatin/activin inhibition.
Best Time
Any time
Method
subcutaneous
Frequency
Every 2 weeks
Half-life
~10-14 days
Cycle Length
Per research protocol
Storage
Refrigerate at 2-8°C.
Published Dosing Ranges
Create an account to access peptide research data.
Contraindications
Create an account to access peptide research data.
Journal of applied physiology (Bethesda, Md. : 1985) 109 (3) :635-42 · 2010-09-01
Drug testing and analysis 17 (10) :1934-1946 · 2025-10-01
PloS one 21 (2) :e0342666 · 2026-01-01
Scientific reports 13 (1) :18882 · 2023-11-02
PloS one 17 (9) :e0273193 · 2022-01-01
Mechanism of Action
Soluble activin receptor type IIB that acts as a decoy, trapping myostatin, activin, and GDF-11 before they can signal. Removes multiple negative regulators of muscle growth simultaneously.
Reported by the community. These may not be supported by clinical evidence and are not medical recommendations.